Видео с ютуба Fda Cber

FDA-NIH 2024 | D1S09 - Regulatory Resources and Avenues for Obtaining Early Guidance from CBER/OTP

FDA-NIH 2024 | D1S09 - Regulatory Resources and Avenues for Obtaining Early Guidance from CBER/OTP
Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”

Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
FDA CBER Cell Therapies and Tissue-Based Products Workshop: Welcome and Opening Remarks

FDA CBER Cell Therapies and Tissue-Based Products Workshop: Welcome and Opening Remarks
CMT and the FDA: Interview with Dr. Peter Marks

CMT and the FDA: Interview with Dr. Peter Marks
FDA Omics Days 2024: Public afternoon sessions

FDA Omics Days 2024: Public afternoon sessions
The FDA answers questions about the first COVID-19 vaccine authorized for use in the US

The FDA answers questions about the first COVID-19 vaccine authorized for use in the US
Indira Hewlett CBER/FDA, US Talk Nanotechnology & Pathogen, GSRS16, NIH Bethesda, Sep 08, 2016

Indira Hewlett CBER/FDA, US Talk Nanotechnology & Pathogen, GSRS16, NIH Bethesda, Sep 08, 2016
Death, Destruction, FDA now says JAB was no Good

Death, Destruction, FDA now says JAB was no Good
2025 CERSI Summit - Panel 4: FDA Chiefs Chat

2025 CERSI Summit - Panel 4: FDA Chiefs Chat
3/21 MRT Public Discussion Meeting: Presentations (FDA Perspective and Committee Overview)

3/21 MRT Public Discussion Meeting: Presentations (FDA Perspective and Committee Overview)
미약사 2분뉴스, FDA CBER 새로운 책임자 & 백신 제약회사 미래. 기사첨가

미약사 2분뉴스, FDA CBER 새로운 책임자 & 백신 제약회사 미래. 기사첨가
Season 2 Episode 39 - Gene Therapy is Fighting Rare Diseases in FDA, NIH Program

Season 2 Episode 39 - Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
Keeping Pace with CGT, Dr Peter Marks, Director CBER, FDA

Keeping Pace with CGT, Dr Peter Marks, Director CBER, FDA
FDA CBER Director Peter Marks chose a more appropriate venue for his lies to ALS patients.

FDA CBER Director Peter Marks chose a more appropriate venue for his lies to ALS patients.
Past Leader Spotlight: Rebecca Devine

Past Leader Spotlight: Rebecca Devine
FDA’s Efforts to Advance the Development and Approval of Cellular and Gene Therapies

FDA’s Efforts to Advance the Development and Approval of Cellular and Gene Therapies